Sacubitril/Valsartan to Reduce Secondary Mitral Regurgitation

Circulation. 2019 Mar 12;139(11):1366-1370. doi: 10.1161/CIRCULATIONAHA.118.038135.

Authors

Wilfried Mullens^{1

2}, Pieter Martens^{1

3}

Affiliations

¹ Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium (W.M., P.M.).
² Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium (W.M.).
³ Doctoral School for Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium (P.M.).

PMID: 30855999
DOI: 10.1161/CIRCULATIONAHA.118.038135

No abstract available

Keywords: Editorials; guideline; heart failure; heart ventricles; mitral valve insufficiency.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Aminobutyrates
Biphenyl Compounds
Drug Combinations
Humans
Mitral Valve Insufficiency*
Neprilysin*
Receptors, Angiotensin
Tetrazoles
Valsartan

Substances

Aminobutyrates
Biphenyl Compounds
Drug Combinations
Receptors, Angiotensin
Tetrazoles
Valsartan
Neprilysin
sacubitril and valsartan sodium hydrate drug combination